Clinical Trials Directory

Trials / Completed

CompletedNCT00596908

123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor

123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor (AIM)

Status
Completed
Phase
Study type
Observational
Enrollment
54 (actual)
Sponsor
Alseres Pharmaceuticals, Inc · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

This study is designed to obtain an imaging training set that will be used to evaluate images in future trials. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S. for use in diagnosing Parkinson disease and related Parkinsonian syndromes. The diagnosis of Parkinsonian syndromes in the U.S. is based on clinical criteria only. The goal is to demonstrate that 123I-ALTROPANE® paired with SPECT imaging permits a more accurate early diagnosis of Parkinson disease than a clinical diagnosis by a general neurologist.

Detailed description

This is a prospective, multi-center, non-randomized, open-label, out patient clinical trial which will include up to 90 subjects, male or female, 40 years of age or older. This study is designed to obtain an imaging training set that will be used to evaluate images in future trials. Up to ninety subjects with upper extremity tremor for less than 2 years duration will be enrolled. Of these, at least thirty Parkinsonian syndromes subjects and at least thirty non-Parkinsonian syndromes subjects as diagnosed by a MDS will be enrolled. Subjects will participate in three study visits over the course of the study period. The screening visit will include an assessment of eligibility as well as the collection of the MDS diagnosis. The second visit, during which all subjects receive a single intravenous injection of 123I-ALTROPANE® followed by SPECT imaging, will include appropriate safety assessments before and after dosing. The third visit will include follow-up safety. The subjects' participation in the study will range between 30 and 40 days.

Conditions

Timeline

Start date
2007-12-01
Completion
2009-03-01
First posted
2008-01-17
Last updated
2009-05-29

Locations

7 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00596908. Inclusion in this directory is not an endorsement.